Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania.

The deal gives the biotech an

Read the full 337 word article

User Sign In